Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ramucirumab

- PMLiVE

IQWiG passes Boehringer lung cancer drug

Germany’s cost assessor says it can extend life in some patients, but benefit it ‘minor'

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

Fighting talk

One thing that grasps my interest is how society has adopted military style language when talking about cancer

Research Partnership

- PMLiVE

The BMJ weighs in on Avastin/Lucentis debate

The UK’s leading medical journal says Avastin should be used for wet AMD to cut costs

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Bowel Cancer UK launches research initiative

Announcement for its R&D commitment comes during Bowel Cancer Awareness Month

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

- PMLiVE

WHO: Medicine costs ‘too high’ for European governments

New report shows transparency and co-operation needed to help reduce drug prices

- PMLiVE

Final NICE ‘no’ for Celgene’s Imnovid

England’s pricing watchdog says multiple myeloma drug is just too expensive for the NHS

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

- PMLiVE

Cancer charity partners with research council for innovation

CRUK teams up with multi-disciplinary groups to help develop new oncology products

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links